# RIVastigmine In Vascular cognitivE Impairment

> **NCT00669344** · PHASE4 · COMPLETED · sponsor: **Singapore General Hospital** · enrollment: 50 (actual)

## Conditions studied

- Cognitive Impairment

## Interventions

- **DRUG:** Exelon (rivastigmine)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00669344
- **Lead sponsor:** Singapore General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2007-04
- **Final completion:** 2008-02
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2017-02-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00669344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00669344, "RIVastigmine In Vascular cognitivE Impairment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00669344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*